Genentech, a member of Basel, Switzerland-based Roche Group, earned priority review status for its drug Lucentis.
The drug is intended to treat myopic choroidal neovascularization, a condition that can lead to vision loss or blindness.
The priority review process, which expedites the review of a drug application to about six months after filing, was created to decrease the time it takes to put new medicines on the market.
If approved, San Francisco-based Genentech would maintain all commercial rights to Lucentis in the U.S., while Roche would hold commercial rights outside the U.S.
More articles on supply chain:
St. Jude Medical issues warning on heart device after 2 patient deaths
Cost is king: 5 thoughts on the hospital supply chain from an expert who's seen both sides of the business
Red Cross stresses need for blood, platelets after hurricane cancels 40 blood drives